We bring innovation to patients by bridging the gap
Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop novel therapies to target high unmet medical needs in oncology and infectious diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery programs and international patient reach. We seek out and identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select global partners to maximize worldwide patient access.
Our ultimate purpose is to develop tomorrow’s standard of care to cure cancer and infectious diseases and to improve patient quality of life.
Debiopharm is not a biotech, but a privately owned, unlisted biopharmaceutical company. That means that we have the freedom to explore where science leads us. Our decision to in-license and develop specific drug candidates are always based on scientific rationale and aimed to respond to patient unmet needs.
-
SEARCH & EVALUATIONDiscover
Do you have a compound?
We scout for new, innovative pharmaceutical drug candidates to go through our full drug development value chaine, from preclinical to registration.
-
BUSINESS DEVELOPMENTDiscover
Are you interested in one of our programs?
We are looking for partners for all projects with a focus on our clinically advanced candidates.
Our program pipeline
We currently have a growing pipeline of projects in development in the areas of oncology, infectious disease, and antibody-drug conjugate (ADC) drug technology.
Discover the members who guide and bring long-term vision to drug development